References
- Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing enterobacteriaceae: variability by site of infection. Arch. Intern. Med. 165(12), 1375–1380 (2005).
- Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections. Crit. Care 12(Suppl. 4), S5 (2008).
- Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48(12), 4574–4581 (2004).
- Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29(12), 1099–1106 (2008).
- Costa D, Poeta P, Briñas L, Sáenz Y, Rodrigues J, Torres C. Detection of CTX-M-1 and TEM-52 β-lactamases in Escherichia coli strains from healthy pets in Portugal. J. Antimicrob. Chemother. 54(5), 960–961 (2004).
- O’Keefe A, Hutton TA, Schifferli DM, Rankin SC. First detection of CTX-M and SHV extended-spectrum β-lactamases in Escherichia coli urinary tract isolates from dogs and cats in the United States. Antimicrob. Agents Chemother. 54(8), 3489–3492 (2010).
- Dokouhaki P, Blondeau JM. Advances in laboratory diagnostic technologies in clinical microbiology and what this means for clinical practice. Clin. Pract. 9(4), 347–352 (2012).
- Herath C, Blondeau JM. Do we really understand what we want or need out of antimicrobial stewardship programs? Clinical Practice. 10(1), 5–9 (2012).
- Mohd Hafiz AA, Staatz CE, Kirkpatrick CM, Lipman J, Roberts JA. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiologica 78(1), 94–104 (2012).